A tax reprieve improves their prospects

Article Excerpt

The U.S. imposed a 2.3% tax on the sale of medical devices in 2013 as part of the Affordable Care Act. However, Congress suspended the tax in 2015, and has now extended that delay till 2020. It’s likely that Congress will ultimately kill the tax. That would give these three companies more cash for research and new growth projects. BECTON DICKINSON & CO. $230 (New York symbol BDX; Conservative Growth Portfolio; Consumer sector; Shares outstanding: 267.2 million; Market cap: $61.4 billion; Price-to-sales ratio: 4.6; Dividend yield: 1.3%; TSINetwork Rating: Above Average; www.bd.com) operates in three segments: Medical, which supplies 51% of the company’s sales, makes a broad array of devices for hospitals, doctors’ offices and other health-care clients; Life Sciences (26%) sells products for collecting and shipping specimens as well as equipment for detecting diseases; and Interventional (23%) makes stents, catheters, needles, drainage and incontinence devices, and surgical tools. On January 1, 2018, Becton completed its $25.0 billion cash-and-stock takeover of rival medical device…